UK markets closed

CVAC Jan 2023 97.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.80000.0000 (0.00%)
As of 01:46PM EDT. Market open.
Full screen
Previous close0.8000
Open0.8000
Bid0.0000
Ask5.0000
Strike97.50
Expiry date2023-01-20
Day's range0.8000 - 0.8000
Contract rangeN/A
Volume1
Open interest6
  • EQS Group

    CureVac Announces Voting Results of General Meeting

    Issuer: CureVac / Key word(s): AGM/EGM22.06.2022 / 22:05 The issuer is solely responsible for the content of this announcement. CureVac Announces Voting Results of General Meeting TÜBINGEN, Germany / BOSTON, USA – June 22, 2022 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general meeting. The shareholders o

  • Simply Wall St.

    What Type Of Shareholders Own The Most Number of CureVac N.V. (NASDAQ:CVAC) Shares?

    The big shareholder groups in CureVac N.V. ( NASDAQ:CVAC ) have power over the company. Insiders often own a large...

  • EQS Group

    CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

    Issuer: CureVac / Key word(s): Takeover08.06.2022 / 22:10 The issuer is solely responsible for the content of this announcement.CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform Acquisition extends CureVac’s capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients’ immune systems to fight cancer Frame’s platform offers potential to develop off-the-shelf and pers